Novocure wins FDA approval for electric field device in lung cancer ...
18 hours ago · Optune Lua’s effectiveness alongside current medical practice could become clearer with readouts from two other trials in lung cancer: Lunar-2, in first-line treatment with a PD-1 and chemo, and Lunar-4, in second-line treatment with a PD-1 following disease progression on a PD-1 alone. Those studies are scheduled to conclude in 2028 and 2026 ...
Novocure's Optune Lua Receives FDA Approval For Lung Cancer …
1 day ago · Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung cancer cells. This innovative technology is based on the use with low ...
FDA Approves Novocure’s Optune Lua® for the ... - Business Wire
3 days ago · Optune Lua is a wearable treatment that delivers Tumor Treating Fields (TTFields), which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death
FDA Approves Novocure’s Optune Lua® for the Treatment of …
4 days ago · Optune Lua is a wearable treatment that delivers Tumor Treating Fields (TTFields), which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.
Novocure wins FDA nod for lung cancer treatment wearable
1 day ago · October 17, 2024 By Sean Whooley. Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer. Optune Lua uses tumor ...
NovoCure scoops FDA approval on wearable for metastatic cancer ...
2 days ago · NovoCure’s Optune Lua, a wearable indicated for use alongside PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel in adult patients with metastatic non-small cell lung cancer (mNSCLC), has received approval from the US FDA.. Approved on the basis of positive Phase III data, the treatment is aimed at patients whose form of cancer has continued to progress on or after a platinum-based regimen.
FDA Approves Optune Lua Device in NSCLC - ajmc.com
2 days ago · Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer ...
FDA Approves Novocure’s Optune Lua For Metastatic Non-Small …
2 days ago · Breaking News. FDA Approves Novocure’s Optune Lua for Metastatic Non-Small Cell Lung Cancer. ... The group treated with Optune Lua concurrently with a PD-1/PD-L1 inhibitor or docetaxel had a median OS of 13.2 months (95% CI, 10.3 to 15.5 months) compared to a median OS of 9.9 months (95% CI, 8.2 to 12.2 months) in the PD-1/PD-L1 inhibitor or ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, …
3 days ago · Emily Bodnar’s rating is based on NovoCure’s recent FDA approval for Optune Lua, which has shown promising results in extending overall survival for metastatic NSCLC patients when used in ...
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in …
2 days ago · Findings from the phase 3 LUNAR trial (NCT02973789) support this approval. The FDA has granted approval to Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC whose disease has progressed on or after a platinum-based regimen. 1. Optune Lua is a portable device that generates alternating ...
- Some results have been removed